,21 The clinical trials—STEP-HFpEF (Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity; NCT04788511), STEP-HFpEF-DM (Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity, and Type 2 Diabetes; NCT04916470), and a dual acting GLP-1/GIP in Participants With Heart Failure With Preserved Ejection Fraction and Obesity; NCT04847557)—are currently recruiting participants with obesity-related HFpEF for treatment with semaglutide or tirzepatide. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.